ReviewFrontiers in immunology2026
Psychological distress as a putative host-state determinant of cancer immunotherapy response.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy has transformed oncology, yet durable benefits remain limited to a subset of patients, and those cases are incompletely explained by tumor-intrinsic biomarkers alone. Growing evidence indicates that the host immune state is a critical contextual determinant of therapeutic response and may itself be shaped by psychological distress. In cancer patients, such distress-related states have been associated with altered neuroendocrine activity and related cortisol regulation, inflammation, reduced natural killer cell function, and broader immune dysregulation. In parallel, preclinical studies show that glucocorticoid and adrenergic signaling can impair antitumor immunity by promoting T-cell dysfunction, metabolic exhaustion, and increased inhibitory signaling, as well as suppressing antigen presentation. Emerging clinical studies in patients receiving immune checkpoint inhibitors further suggest that emotional distress before immunotherapy initiation is associated with poorer progression-free survival, response, and overall survival outcomes in several cancer settings, including non-small-cell lung cancer, gastroesophageal cancer, gastric cancer, and recurrent high-grade glioma. As these patient data remain largely observational, current evidence supports psychological distress as a putative host-state modifier or correlate, rather than as a proven causal determinant, of immunotherapy response. These observations support a psycho-neuro-immune framework in which psychological distress may identify or contribute to a host state that is less permissive for effective immunotherapy. Here, we review evidence linking host immune competence to immunotherapy efficacy, summarize clinical and molecular data connecting distress to immune dysregulation in cancer, and incorporate emerging evidence that brain-body signaling may shape tumor immunity through neural, endocrine, and immune pathways. We propose that psychological distress should be considered not merely as a parallel quality-of-life variable, but as a biologically relevant and clinically verifiable host-state factor with implications for biomarker development and future host-modulation immunotherapy trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.